BI and ViraTherapeutics collaborate for oncolytic virus platform; BI has option to acquire ViraTherapeutics
- Gene Therapy, Cell Therapy
- Includes M&A Option
- R+D and Marketing-Licensing
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.